144 related articles for article (PubMed ID: 27649548)
1. A DFT-based QSAR study on inhibition of human dihydrofolate reductase.
Karabulut S; Sizochenko N; Orhan A; Leszczynski J
J Mol Graph Model; 2016 Nov; 70():23-29. PubMed ID: 27649548
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure activity relationship study of 2,4,6-trisubstituted-s-triazine derivatives as antimalarial inhibitors of Plasmodium falciparum dihydrofolate reductase.
Ojha H; Gahlot P; Tiwari AK; Pathak M; Kakkar R
Chem Biol Drug Des; 2011 Jan; 77(1):57-62. PubMed ID: 20958921
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
Adane L; Bharatam PV
J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
[TBL] [Abstract][Full Text] [Related]
4. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors.
Santos-Filho OA; Mishra RK; Hopfinger AJ
J Comput Aided Mol Des; 2001 Sep; 15(9):787-810. PubMed ID: 11776291
[TBL] [Abstract][Full Text] [Related]
5. CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase.
Santos-Filho OA; Forge D; Hoelz LV; de Freitas GB; Marinho TO; Araújo JQ; Albuquerque MG; de Alencastro RB; Boechat N
J Mol Model; 2012 Sep; 18(9):4061-72. PubMed ID: 22527273
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies on the inhibitory activity of trimethoprim analogues against Escherichia coli dihydrofolate reductase.
Vijayaraj R; Devi ML; Subramanian V; Chattaraj PK
Chem Biol Drug Des; 2012 Jun; 79(6):935-42. PubMed ID: 22304783
[TBL] [Abstract][Full Text] [Related]
7. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives.
Hecht D; Cheung M; Fogel GB
Biosystems; 2008 Apr; 92(1):10-5. PubMed ID: 18160210
[TBL] [Abstract][Full Text] [Related]
8. Generation of QSAR sets with a self-organizing map.
Guha R; Serra JR; Jurs PC
J Mol Graph Model; 2004 Sep; 23(1):1-14. PubMed ID: 15331049
[TBL] [Abstract][Full Text] [Related]
9. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
10. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
Gangjee A; Lin X
J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
12. Self-organizing neural networks for modeling robust 3D and 4D QSAR: application to dihydrofolate reductase inhibitors.
Polanski J; Bak A; Gieleciak R; Magdziarz T
Molecules; 2004 Dec; 9(12):1148-59. PubMed ID: 18007509
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration.
Tosso RD; Andujar SA; Gutierrez L; Angelina E; Rodríguez R; Nogueras M; Baldoni H; Suvire FD; Cobo J; Enriz RD
J Chem Inf Model; 2013 Aug; 53(8):2018-32. PubMed ID: 23834278
[TBL] [Abstract][Full Text] [Related]
14. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis.
Mattioni BE; Jurs PC
J Mol Graph Model; 2003 Mar; 21(5):391-419. PubMed ID: 12543137
[TBL] [Abstract][Full Text] [Related]
15. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
Nelson RG; Rosowsky A
Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
[TBL] [Abstract][Full Text] [Related]
16. Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium.
Bolstad DB; Bolstad ES; Frey KM; Wright DL; Anderson AC
J Med Chem; 2008 Nov; 51(21):6839-52. PubMed ID: 18834108
[TBL] [Abstract][Full Text] [Related]
17. Investigating the selectivity of potential new inhibitors of dihydrofolate reductase from Yersinia pestis designed by molecular modeling.
Bastos LDC; de Souza FR; Pereira Souza LM; Forgione P; Cuya T; de Alencastro RB; Pimentel AS; Celmar Costa França T
J Biomol Struct Dyn; 2019 Mar; 37(5):1170-1176. PubMed ID: 29542379
[No Abstract] [Full Text] [Related]
18. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Singh P; Kaur M; Sachdeva S
J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
[TBL] [Abstract][Full Text] [Related]
19. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
20. Characterization of dihydrofolate reductases from multiple strains of Plasmodium falciparum using mathematical descriptors of their inhibitors.
Basak SC; Mills D; Hawkins DM
Chem Biodivers; 2011 Mar; 8(3):440-53. PubMed ID: 21404427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
